UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant to Rule13a-16 or15d-16
under the Securities Exchange Act of 1934
Dated September 30, 2019
Commission File Number001-37518
Benitec Biopharma Limited
(Translation of registrant’s name into English)
Level 14, William Street
Melbourne 3000, VIC, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F. Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b): Not applicable
This report onForm 6-K is incorporated by reference in the Prospectus Supplement of Benitec Biopharma Limited filed with the U.S. Securities and Exchange Commission (“SEC”) on September 30, 2019, and shall be deemed to be a part thereof from the date on which this report is furnished to the SEC, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Benitec Biopharma Limited | ||||||
| Date: September 30, 2019 | By: | /s/ Jerel Banks_ | ||||
| Name: | Jerel Banks | |||||
| Title: | Chief Executive Officer | |||||
3